drugset / Trial / NCT00803556
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies
Timeline
- Start
- 2006-01
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | alvespimycin | Small molecule | 60 mg/m2 | Intravenous |
| Subject | alvespimycin | Small molecule | 100 mg/m2 | Intravenous |